Inclusion Criteria:

Documented locally advanced or metastatic adenocarcinoma of the biliary tract; Adequate
bone marrow, hepatic and renal function; Bilirubin <= 1.5 times the upper limit of normal;
Age 18 years or older; Predicted life expectancy 12 weeks or more; Prior surgery and
radiation therapy permitted provided patient has recovered adequately; At least 1 target
lesion >= 20 mm (or >= 10 mm on spiral CT-scan); ECOG Performance Status 0-2; No prior
chemotherapy for locally advanced or metastatic disease. Adjuvant/neo-adjuvant permitted
if therapy was completed at least 12 months prior to study entry;

Exclusion Criteria:

Concurrent anticancer therapy while on study; History of other malignancy within the past
3 years except basal or squamous cell carcinoma or in situ cervical cancer; Symptomatic
brain metastases which are not stable or have required radiation in the past 28 days;